KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for Cardlytics (CDLX) over the last 9 years, with Q3 2025 value amounting to $7.9 million.

  • Cardlytics' Cost of Revenue fell 4024.92% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year decrease of 2187.05%. This contributed to the annual value of $52.6 million for FY2024, which is 831.69% down from last year.
  • As of Q3 2025, Cardlytics' Cost of Revenue stood at $7.9 million, which was down 4024.92% from $11.3 million recorded in Q2 2025.
  • Cardlytics' 5-year Cost of Revenue high stood at $22.0 million for Q2 2022, and its period low was $7.9 million during Q3 2025.
  • For the 5-year period, Cardlytics' Cost of Revenue averaged around $14.9 million, with its median value being $14.1 million (2024).
  • Per our database at Business Quant, Cardlytics' Cost of Revenue skyrocketed by 6398.85% in 2021 and then crashed by 4024.92% in 2025.
  • Quarter analysis of 5 years shows Cardlytics' Cost of Revenue stood at $19.0 million in 2021, then dropped by 11.44% to $16.8 million in 2022, then fell by 16.13% to $14.1 million in 2023, then dropped by 19.62% to $11.3 million in 2024, then crashed by 30.66% to $7.9 million in 2025.
  • Its Cost of Revenue was $7.9 million in Q3 2025, compared to $11.3 million in Q2 2025 and $12.8 million in Q1 2025.